CA3048157A1 - Methods of treatment with anti-factor xi/xia antibodies - Google Patents

Methods of treatment with anti-factor xi/xia antibodies Download PDF

Info

Publication number
CA3048157A1
CA3048157A1 CA3048157A CA3048157A CA3048157A1 CA 3048157 A1 CA3048157 A1 CA 3048157A1 CA 3048157 A CA3048157 A CA 3048157A CA 3048157 A CA3048157 A CA 3048157A CA 3048157 A1 CA3048157 A1 CA 3048157A1
Authority
CA
Canada
Prior art keywords
antibody
seq
fxi
amino acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3048157A
Other languages
English (en)
French (fr)
Inventor
Carola Friedman
Yasser Khder
Martin Lefkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3048157A1 publication Critical patent/CA3048157A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3048157A 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies Pending CA3048157A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438654P 2016-12-23 2016-12-23
US62/438,654 2016-12-23
US201762589851P 2017-11-22 2017-11-22
US62/589,851 2017-11-22
PCT/IB2017/058345 WO2018116267A2 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Publications (1)

Publication Number Publication Date
CA3048157A1 true CA3048157A1 (en) 2018-06-28

Family

ID=61022382

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3048157A Pending CA3048157A1 (en) 2016-12-23 2017-12-22 Methods of treatment with anti-factor xi/xia antibodies

Country Status (9)

Country Link
US (3) US20200231701A1 (https=)
EP (1) EP3558370A2 (https=)
JP (3) JP7110199B2 (https=)
KR (3) KR102702288B1 (https=)
CN (2) CN110325211A (https=)
AU (2) AU2017383537B2 (https=)
CA (1) CA3048157A1 (https=)
IL (2) IL267519B2 (https=)
WO (1) WO2018116267A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106715473B (zh) 2014-10-01 2021-11-23 免疫医疗有限公司 替格瑞洛的抗体及其使用方法
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
IL267538B2 (en) 2016-12-23 2024-05-01 Novartis Ag Antibodies against factor XI and methods for use in preventing, treating, managing or reducing the risk of thromboembolic disorder or stroke in a patient
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PL3852617T3 (pl) * 2018-09-20 2026-01-26 SFJ Pharma X, Inc. Zastosowanie fragmentów przeciwciała do odwrócenia aktywności tikagreloru
JP7650807B2 (ja) * 2019-04-16 2025-03-25 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＦＸＩ／ＦＸＩａ抗体及びその使用
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
BR112022012064A2 (pt) * 2019-12-20 2022-08-30 Anthos Therapeutics Inc Formulação de distribuição de fármaco intravenosa, frasco compreendendo a mesma e método de tratamento de um sujeito acometido por ou em risco de desenvolver um distúrbio tromboembólico
EP4177274A4 (en) * 2020-07-02 2024-04-03 Beijing Tuo Jie Biopharmaceutical Co. Ltd. Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法
CN120173947A (zh) * 2024-03-28 2025-06-20 施能康医药科技(苏州)有限公司 靶向凝血因子xi的核酸及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20030235587A1 (en) * 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
BR9913435A (pt) * 1998-08-28 2001-09-25 Genentech Inc Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica
EP2206720A1 (en) 2000-04-12 2010-07-14 Human Genome Sciences, Inc. Albumin fusion proteins
BR0015872A (pt) * 2000-05-15 2004-08-03 Smithkline Beecham Corp Agentes antitrombóticos
PT3002298T (pt) * 2007-11-21 2019-11-20 Univ Oregon Health & Science Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
WO2009154461A1 (en) 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
US8388959B2 (en) * 2008-12-18 2013-03-05 Oregon Health & Science University Anti-fXI antibodies and methods of use
IL212911A0 (en) * 2011-05-16 2011-07-31 Omrix Biopharmaceuticals Ltd Immunoglobulin reduced in thrombogenic contaminants and preparation thereof
EP2847228B1 (en) * 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
CN110325211A (zh) 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法

Also Published As

Publication number Publication date
IL267519A (en) 2019-08-29
WO2018116267A3 (en) 2018-08-02
IL316673A (en) 2024-12-01
KR20190099256A (ko) 2019-08-26
KR102702288B1 (ko) 2024-09-05
US20200231701A1 (en) 2020-07-23
KR102918597B1 (ko) 2026-01-28
JP7500662B2 (ja) 2024-06-17
AU2024287181A1 (en) 2025-03-06
IL267519B1 (en) 2024-12-01
CN110325211A (zh) 2019-10-11
JP2020504110A (ja) 2020-02-06
JP7110199B2 (ja) 2022-08-01
US20250197522A1 (en) 2025-06-19
AU2017383537B2 (en) 2024-10-03
EP3558370A2 (en) 2019-10-30
JP2022141831A (ja) 2022-09-29
KR20260023597A (ko) 2026-02-20
IL267519B2 (en) 2025-04-01
US20230002507A1 (en) 2023-01-05
AU2017383537A1 (en) 2019-06-27
JP2024116221A (ja) 2024-08-27
KR20240134248A (ko) 2024-09-06
WO2018116267A2 (en) 2018-06-28
CN118320078A (zh) 2024-07-12

Similar Documents

Publication Publication Date Title
US20250197522A1 (en) Methods of treatment with anti-factor xi/xia antibodies
US20240067750A1 (en) Factor xi antibodies and methods of use
US12012464B2 (en) Factor XI antibodies and methods of use
CA3048156C (en) Factor xi antibodies and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220921

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250603

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250603

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250603

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250926

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251001

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251001

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251001

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251001

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251118

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251222

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260203